AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02368899 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control (AC)
Description: These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
Study NCT02765386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid fittings for cochlear implant recipients
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin (active name: Bleomycin Sulfate)
Description: Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.~Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses.
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin (active name: Bleomycin Sulfate)
Description: Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.~Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses.
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF (Pegfilgrastim)
Description: Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated G-CSF (Pegfilgrastim)
Description: Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 21-day cycle for 4 cycles.~Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 14-day cycle for 4 cycles.
Study NCT02582697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 21-day cycle for 4 cycles.~Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 14-day cycle for 4 cycles.
Study NCT01052389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
Study NCT01052389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
Study NCT01052389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day).
Study NCT00505414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol in the Titration Phase
Study NCT00505414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine in the Maintenance Phase
Description: Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase.
Study NCT00505414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase
Description: Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
Study NCT00505414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol in the Maintenance Phase
Description: The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
Study NCT00505414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine in the Titration Phase
Description: After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
Study NCT04660578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACCSS
Description: A. Chohan Continuous Squeezing Suture (ACCSS)
Study NCT04128124 — intervention group
Intervention type: OTHER
Intervention: processing signals of airway pressure and airway flow to calculate entropy
Description: processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
Study NCT01397240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albis Tab
Description: 2 Tab, twice a day, 12 weeks
Study NCT01397240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Tab, twice a day, 12 weeks
Study NCT03503383 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Health Questionnaire-9
Description: PHQ-9 for assessing and monitoring depression severity
Study NCT03503383 — intervention group
Intervention type: BEHAVIORAL
Intervention: Generalized Anxiety Disorder Scale (GAD-7)
Description: to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder
Study NCT03367910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant
Description: 150mL of FMT product RBX2660 delivered via enema
Study NCT01317706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of cervical status
Description: Assessment of cervical status based on Bishop score versus sonographically measured cervical length
Study NCT01560871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity IMT plus walking
Description: The IMT intensity was set at 60% of PImax which was reassessed weekly. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.~For the walking program, it was the same as the one for the control group.
Study NCT01560871 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Low-intensity IMT plus walking
Description: The IMT training was 3 sets of 10 repetitions, or when the participant felt tired. Participants returned to our facility every week to reassess PImax.~For the walking program, each participant was given a pedometer and a heart rate monitor to track daily step counts and heart rate. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion scale. Participants began at least 10 to 15 minutes, once to twice a day, for 7 days a week, and eventually progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate.
Study NCT02643745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrology Intervention
Description: 1. pre-operative study:~   * Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~  * Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~2. optimise the patient' s overall condition with a pre-operative strategy:~   * Obesity control~  * Control protein, caloric, salt intake~  * Stop smoking~  * Good glycemic control~  * Start ACEI/ARA II if there is proteinuria~  * Start additional antihypertensive drug if required~  * Start hypolipemic treatment if required~  * Start hyperuricemia treatment if required~  * Start AAS, clopidogrel if it is necessary (prophylaxis)~  * Phosphate control~  * Anemia control~  * Metabolic acidosis correction
Study NCT02004106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6895882
Description: Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
Study NCT02933307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HealthPatch
Description: The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
Study NCT02933307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViSi Mobile
Description: ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
Study NCT01010997 — intervention group
Intervention type: DEVICE
Intervention: Foresee Home
Description: using the Foresee home device
Study NCT03307122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Infant Formula 1
Description: Routine infant formula with probiotic
Study NCT03307122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Infant Formula 2
Description: Routine infant formula with probiotic and prebiotic
Study NCT01721746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-936558
Study NCT01721746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Study NCT01721746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT01721746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT03326752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DV281
Description: - Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
Study NCT03326752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath Actuated Nebulizer
Description: Breath-actuated, electronic system designed to aerosolize liquid medication.
Study NCT03326752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DV281 (RP2D)
Description: - Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
Study NCT03127878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT03127878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT04532762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal spray
Description: Application of a nasal spray
Study NCT04532762 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nasal spray
Description: Application of a nasal spray
Study NCT00738985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ezetimibe/simvastatin 10/20 mg + placebo
Description: Patients will receive placebo (sugar tablets) for up to 22 weeks.
Study NCT00738985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe/simvastatin 10/20 mg + MK0524A
Description: ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
Study NCT00630136 — intervention group
Intervention type: BEHAVIORAL
Intervention: interview
Description: The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (low dose)
Description: Placebo tablets once a day
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (low dose)
Description: Placebo tablets once a day
Study NCT03326752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Approved Anti-PD-1 Inhibitor
Description: FDA approved Anti-PD-1 Inhibitor
Study NCT04478500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.
Study NCT04478500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Description: Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.
Study NCT03933020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR active video game intervention
Description: The Microsoft VR active game program will consist of 3 weekly sessions of 45 minutes each combining 3 different types of exercise
Study NCT03933020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational session
Description: This consists of two education discussion sessions on the benefits of exercise for people with MS. The investigator MS specialists will conduct these sessions either by phone or at the time of a clinic visit and will also discuss difficulties encountered by participants with adherence.
Study NCT03933020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Management of Physical Activity
Description: Routine discussion of lifestyle factors including physical activity during clinic visits
Study NCT04006509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatally Delivered Lactation Educational Program
Description: The support person (SP) of mothers at risk for preterm birth will be educated on how to use a breast pump and instructions regarding breast milk expression and have a pump in their hospital room
Study NCT01738191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
Study NCT01738191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01440387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLULAVAL® QUADRIVALENT
Description: Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups
Study NCT04481165 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Oral interview and written questions
Study NCT02716506 — intervention group
Intervention type: PROCEDURE
Intervention: POP surgery
Description: Any surgical procedure that is done to treat the symptomatic POP
Study NCT03025347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants complete a resting control condition instead of a run.
Study NCT03025347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants complete a 60 minute run at 70% of their maximal oxygen uptake
Study NCT03370458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DR7
Description: This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
Study NCT03370458 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
Study NCT00208234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 0.016 mg/kg IgE
Study NCT00208234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Omalizumab
Description: Placebo
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (mid dose)
Description: Placebo tablets once a day
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (high dose)
Description: Placebo tablets once a day
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets low dose once a day
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (high dose)
Description: Placebo tablets once a day
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets mid-high dose once a day
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets high dose once a day
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (mid dose)
Description: Placebo tablets once a day
Study NCT00208234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Monoclonal antibody against IgE. 0.016 mg/kg IgE
Study NCT03126955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Operative CISS-MRI Sequences
Description: Compare pre-operative MRI diagnosis to intra-operative findings on if both are in agreement
Study NCT03126955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Operative Interictal Laryngoscopy
Description: Compare pre-operative laryngoscopy diagnosis to intra-operative findings on if both are in agreement
Study NCT03126955 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Operative Unilateral and Contralateral Botox
Description: Compare pre-operative diagnosis using Botox to intra-operative findings on if both are in agreement
Study NCT04087616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBIT
Description: The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.
Study NCT04087616 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: waiting list
Description: Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
Study NCT02824588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: Training mental flexibility
Study NCT01193218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets mid-low dose once a day
Study NCT04012723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MY01 Continuous Compartmental Pressure Monitor
Description: The MY01 Continuous Compartmental Pressure Monitor is intended for real-time and continuous measurement of compartmental pressures.